ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome

ClinicalTrials.gov ID: NCT02915159

Public ClinicalTrials.gov record NCT02915159. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 5:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Primary Sjögrens Syndrome

Study identification

NCT ID
NCT02915159
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
250 participants

Conditions and interventions

Interventions

  • Abatacept Biological
  • Placebo Other

Biological · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 5, 2016
Primary completion
Aug 6, 2018
Completion
Jul 22, 2019
Last update posted
Aug 9, 2020

2016 – 2019

United States locations

U.S. sites
19
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
St. Jude Hospital Yorba Linda Fullerton California 92835
Riverside Medical Clinic Riverside California 92506
Colorado Arthritis Associates Lakewood Colorado 80228
North Georgia Rheumatology Group Lawrenceville Georgia 30046
Intermountain Research Center Inc. Boise Idaho 83702
Johns Hopkins University Baltimore Maryland 21224
Clinical Pharmacology Study Group Worcester Massachusetts 01605
St. Paul Rheumatology, P.A. Eagan Minnesota 55121
Northwell Health Great Neck New York 11021
Local Institution Charlotte North Carolina 28203
Joint and Muscle Medical Care and Research Institute (JMMCRI) Charlotte North Carolina 28204
Duke Clinical Research Unit, Duke Univ Med Ctr, Duke South Durham North Carolina 27710
Health Research Of Oklahoma Oklahoma City Oklahoma 73103
East Penn Rheumatology Bethlehem Pennsylvania 18015
Altoona Center For Clinical Research Duncansville Pennsylvania 16635-8406
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213
West Tennessee Research Institute Jackson Tennessee 38305
Metroplex Clinical Research Center Dallas Texas 75231
Scott Zashin Inc. Dallas Texas 75231

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02915159, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 9, 2020 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02915159 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →